29 Mar 09
Posted in Glucose control at 0:08 by Laci
By D E Griesdale, R J de Souza, R M van Dam, D K Heyland, D J Cook, A Malhotra, R Dhaliwal, W R Henderson, D R Chittock, S Finfer, D Talmor
CMAJ 2009;180:821-827
Hyperglycemia is associated with increased mortality in critically ill patients. Randomized trials of intensive insulin therapy have reported inconsistent effects on mortality and increased rates of severe hypoglycemia. We conducted a meta-analysis to update the totality of evidence regarding the influence of intensive insulin therapy compared with conventional insulin therapy on mortality and severe hypoglycemia in the intensive care unit (ICU).
Methods
We conducted searches of electronic databases, abstracts from scientific conferences and bibliographies of relevant articles. We included published randomized controlled trials conducted in the ICU that directly compared intensive insulin therapy with conventional glucose management and that documented mortality. We included in our meta-analysis the data from the recent NICE-SUGAR (Normoglycemia in Intensive Care Evaluation — Survival Using Glucose Algorithm Regulation) study.
Results
We included 26 trials involving a total of 13 567 patients in our meta-analysis. Among the 26 trials that reported mortality, the pooled relative risk (RR) of death with intensive insulin therapy compared with conventional therapy was 0.93 (95% confidence interval [CI] 0.83–1.04). Among the 14 trials that reported hypoglycemia, the pooled RR with intensive insulin therapy was 6.0 (95% CI 4.5–8.0). The ICU setting was a contributing factor, with patients in surgical ICUs appearing to benefit from intensive insulin therapy (RR 0.63, 95% CI 0.44–0.91); patients in the other ICU settings did not (medical ICU: RR 1.0, 95% CI 0.78–1.28; mixed ICU: RR 0.99, 95% CI 0.86–1.12). The different targets of intensive insulin therapy (glucose level ≤ 6.1 mmol/L v. ≤ 8.3 mmol/L) did not influence either mortality or risk of hypoglycemia.
Interpretation
Intensive insulin therapy significantly increased the risk of hypoglycemia and conferred no overall mortality benefit among critically ill patients. However, this therapy may be beneficial to patients admitted to a surgical ICU.
Permalink
28 Mar 09
Posted in Glucose control at 13:58 by Laci
By The NICE-SUGAR Study Investigators
NEJM 2009;360:1283-1297
The optimal target range for blood glucose in critically ill patients remains unclear.
Methods
Within 24 hours after admission to an intensive care unit (ICU), adults who were expected to require treatment in the ICU on 3 or more consecutive days were randomly assigned to undergo either intensive glucose control, with a target blood glucose range of 81 to 108 mg per deciliter (4.5 to 6.0 mmol per liter), or conventional glucose control, with a target of 180 mg or less per deciliter (10.0 mmol or less per liter). We defined the primary end point as death from any cause within 90 days after randomization.
Results
Of the 6104 patients who underwent randomization, 3054 were assigned to undergo intensive control and 3050 to undergo conventional control; data with regard to the primary outcome at day 90 were available for 3010 and 3012 patients, respectively. The two groups had similar characteristics at baseline. A total of 829 patients (27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control group died (odds ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 1.28; P=0.02). The treatment effect did not differ significantly between operative (surgical) patients and nonoperative (medical) patients (odds ratio for death in the intensive-control group, 1.31 and 1.07, respectively; P=0.10). Severe hypoglycemia (blood glucose level, ≤40 mg per deciliter [2.2 mmol per liter]) was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the conventional-control group (P<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU (P=0.84) or hospital (P=0.86) or the median number of days of mechanical ventilation (P=0.56) or renal-replacement therapy (P=0.39).
Conclusions
In this large, international, randomized trial, we found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter.
Permalink
Posted in Fluid management, Monitoring at 1:43 by Laci
By M Biais, K Nouette-Gaulain, V Cottenceau, P Revel and F Sztark
BJA 2008;101:761-768
Stroke volume variation (SVV) is able to predict adequately the individual response to fluid loading. Our objective was to assess whether the SVV measured by a new algorithm (VigileoTM; FlotracTM) can predict fluid responsiveness.
Methods
Forty mechanically ventilated patients undergoing liver transplantation, who needed volume expansion (VE), were included. VE was done with albumin (4%) 20 mlxBMI over 20 min. SVV, pulse pressure variation (PPV), central venous pressure (CVP), and pulmonary artery occlusion pressure (PAOP) were measured immediately before and after VE. Cardiac output (CO) measured by transthoracic echocardiography (CO-TTE) was used to define responder patients if CO increased by 15% or more after VE, or non-responder otherwise. CO obtained with the pulmonary artery catheter (CO-PAC) and with Vigileo (CO-Vigileo) were also recorded.
Results
Five patients were excluded. Seventeen patients were responders (Rs) and 18 were non-responders (NRs). Before VE (i) SVV and PPV were higher in Rs and (ii) CVP and PAOP were lower in Rs. Baseline SVV and PPV correlated with change in CO induced by VE (respectively, r2=0.72, P<0.0001; r2=0.84, P<0.0001). An SVV threshold of >10% discriminated Rs with a sensitivity of 94% and a specificity of 94%. After VE, the decrease in SVV was significantly correlated with the increase in CO (r2=0.51; P<0.0001). There was no difference between the area under the ROC curves of SVV and PPV. After VE, the change in CO-Vigileo was closely correlated with change in CO-TTE (r2=0.74, P<0.0001) and with change in CO-PAC (r2=0.77, P<0.0001).
Conclusions
The SVV obtained by the Vigileo system may be used as a predictor of fluid responsiveness in patients with circulatory failure after liver transplantation. CO-Vigileo is able to track the change in CO induced by VE.
Permalink
25 Mar 09
Posted in Pre-operatie evaluation at 0:07 by Laci
By H. Tønnesen, P. R. Nielsen, J. B. Lauritzen, and A. M. Møller
Br. J. Anaesth. 2009 102: 297-306
Smoking and hazardous drinking are common and important risk factors for an increased rate of complications after surgery. The underlying pathophysiological mechanisms include organic dysfunctions that can recover with abstinence. Abstinence starting 3–8 weeks before surgery will significantly reduce the incidence of several serious postoperative complications, such as wound and cardiopulmonary complications and infections. However, this intervention must be intensive to obtain sufficient effect on surgical complications. All patients presenting for surgery should be questioned regarding smoking and hazardous drinking, and interventions appropriate for the surgical setting applied.
Permalink
« Previous entries Next Page » Next Page »